Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 8—August 2022
Dispatch

Effectiveness of Naturally Acquired and Vaccine-Induced Immune Responses to SARS-CoV-2 Mu Variant

Edmilson F. de Oliveira-Filho1, Bladimiro Rincon-Orozco1, Natalia Jones-Cifuentes, Brigitte Peña-López, Barbara Mühlemann, Christian Drosten, Andres Moreira-Soto, and Jan Felix DrexlerComments to Author 
Author affiliations: Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany (E.F. de Oliveira-Filho, B. Mühlemann, C. Drosten, A. Moreira-Soto, J.F. Drexler); Universidad Industrial de Santander School of Medicine, Bucaramanga, Colombia (B. Rincon-Orozco, N. Jones-Cifuentes, B. Peña-López); German Centre for Infection Research, Berlin (B. Mühlemann, C. Drosten, J.F. Drexler)

Main Article

Table 2

ELISA results and endpoint titers for vaccinee and naturally infected individual serum samples from persons in Colombia*

Group Patient ID Nucleocapsid IgG ELISA† Neutralizing titer by PRNT50
WT Mu Alpha Beta Gamma Delta Omicron
AstraZeneca
 AZ2 0.15 204 41 154 79 64 77 13
AZ3 0.07 453 123 381 305 306 470 25
AZ4 0.11 75 3 91 16 20 24 6
AZ5 0.12 76 9 104 3 13 29 2
AZ6 0.13 34 4 45 3 23 15 0
AZ9 0.08 179 35 189 75 128 84 10
AZ10
 0.07
 319
 9
 153
 47
 55
 26
 8
Pfizer-BioNTech
 PF1 0.14 119 9 85 1 18 38 3
PF2 0.04 28 3 43 35 15 17 3
PF3 0.15 262 62 158 130 101 149 19
PF4 0.06 754 121 715 204 226 187 43
PF5 0.05 501 87 320 48 91 259 9
PF6 0.07 123 10 119 52 15 11 3
PF7 0.19 214 9 70 5 0 125 3
PF8 0.05 207 18 167 28 25 66 3
PF9 0.09 715 10 273 0 46 108 2
PF10
 0.62
 1043
 132
 1036
 343
 333
 799
 47
Sinovac
 SVN1 2.96 51 54 72 36 66 83 0
SVN2 1.68 47 9 24 23 21 22 0
SVN3 0.46 41 6 1 1 18 1 0
SVN4 2.43 118 61 151 111 89 87 25
SVN7 0.97 363 162 347 407 188 259 56
SVN8 0.81 303 5 93 26 30 61 5
SVN9 0.69 53 0 32 3 15 35 0
SVN10 1.61 65 4 27 0 10 66 1
SVN12 0.29 52 8 52 1 20 21 0
SVN13 0.39 387 24 126 126 35 130 7
SVN15 2.81 145 175 168 197 147 133 19
SVN16 0.40 67 2 6 25 10 21 3
SVN17 0.07 24 1 1 5 0 15 3
SVN18 0.37 65 0 3 4 0 24 7
SVN20
 1.88
 686
 464
 612
 155
 131
 503
 16
Naturally infected EA210 ND 696 146 825 595 167 177 2
EA234 ND 142 4 86 83 67 9 0
EA238 ND 1,080 48 1080 314 541 79 5
EA245 ND 70 2 61 154 44 0 0
EA332 ND 93 10 43 94 1 20 0
EA334 ND 140 6 74 115 7 16 3
EA340 ND 77 2 24 61 0 14 2
EA352 ND 1,080 113 1,080 578 870 59 3
EA354 ND 336 119 423 972 90 628 0
EA380 ND 918 43 281 630 151 63 17
EA396 ND 139 24 98 88 14 21 0
EA413 ND 1,080 18 864 1,080 260 17 11
EA422 ND 2 20 28 6 123 100 0
EA439 ND 398 171 283 812 79 62 9
EA485 ND 357 87 531 206 114 14 0
EA501 ND 17 13 86 80 1 0 2
EA520 ND 166 36 154 211 16 141 1

*AstraZeneca (AZD1222), https://www.astrazeneca.com; Pfizer-BioNTech (BNT162b2), https://www.pfizer.com; Sinovac (CoronaVac), http://www.sinovac.com. ND, not determined; PRNT50, 50% plaque reduction neutralization test; WT, wild-type. †Cut-off ≥0.8 was considered positive.

Main Article

1These first authors contributed equally to this article.

Page created: June 03, 2022
Page updated: September 08, 2022
Page reviewed: September 08, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external